MX2021003654A - Metodo para seleccionar neoepitopes. - Google Patents
Metodo para seleccionar neoepitopes.Info
- Publication number
- MX2021003654A MX2021003654A MX2021003654A MX2021003654A MX2021003654A MX 2021003654 A MX2021003654 A MX 2021003654A MX 2021003654 A MX2021003654 A MX 2021003654A MX 2021003654 A MX2021003654 A MX 2021003654A MX 2021003654 A MX2021003654 A MX 2021003654A
- Authority
- MX
- Mexico
- Prior art keywords
- selecting
- neoepitopes
- present
- mhc
- selecting neoepitopes
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18197172 | 2018-09-27 | ||
| PCT/EP2019/076210 WO2020065023A1 (en) | 2018-09-27 | 2019-09-27 | Method for selecting neoepitopes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003654A true MX2021003654A (es) | 2021-05-28 |
Family
ID=63794302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003654A MX2021003654A (es) | 2018-09-27 | 2019-09-27 | Metodo para seleccionar neoepitopes. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12462898B2 (https=) |
| EP (1) | EP3856957A1 (https=) |
| JP (1) | JP7585195B2 (https=) |
| KR (1) | KR102902460B1 (https=) |
| CN (1) | CN112771214B (https=) |
| AU (1) | AU2019346023B2 (https=) |
| BR (1) | BR112021005702A8 (https=) |
| CA (1) | CA3111903A1 (https=) |
| IL (1) | IL281771B2 (https=) |
| MX (1) | MX2021003654A (https=) |
| SG (1) | SG11202101965QA (https=) |
| WO (1) | WO2020065023A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020221783A1 (en) * | 2019-04-29 | 2020-11-05 | Vaccibody As | Methods for pre-selection of neoepitopes |
| CN116802738A (zh) * | 2020-11-06 | 2023-09-22 | 亚马逊科技公司 | 为个体化癌症疫苗选择新抗原 |
| GB202102606D0 (en) * | 2021-02-24 | 2021-04-07 | Univ Oxford Innovation Ltd | Treatment of ovarian cancer minimal residual disease |
| KR20230164118A (ko) | 2021-03-26 | 2023-12-01 | 니코데 테라퓨틱스 에이에스에이 | 암 치료를 위한 치료 조합 |
| BR112023023260A2 (pt) | 2021-05-10 | 2024-01-30 | Nykode Therapeutics ASA | Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica |
| WO2022238381A2 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunotherapy constructs for treatment of disease |
| WO2023244997A1 (en) * | 2022-06-13 | 2023-12-21 | The University Of North Carolina At Chapel Hill | Compositions and methods for inducing anticancer immunity |
| WO2024092025A1 (en) | 2022-10-25 | 2024-05-02 | Nykode Therapeutics ASA | Constructs and their use |
| KR102857635B1 (ko) * | 2022-11-08 | 2025-09-10 | 인바이츠지노믹스 주식회사 | 면역원성이 높은 유사체를 디자인하는 방법 및 이를 이용한 장치 |
| WO2024100196A1 (en) | 2022-11-09 | 2024-05-16 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
| WO2024216073A1 (en) * | 2023-04-14 | 2024-10-17 | The Trustees Of Columbia University In The City Of New York | Engineered microbes comprising tumor neoantigen vectors for cancer immunotherapy |
| US20250232833A1 (en) * | 2024-01-13 | 2025-07-17 | Noergaard Anders Kaare | Cyclin D1 Based Cancer Vaccine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2569633B1 (en) | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| PL3892295T3 (pl) | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| EP3417874B1 (en) | 2012-11-28 | 2024-09-11 | BioNTech SE | Individualized vaccines for cancer |
| EP2983702A2 (en) | 2013-04-07 | 2016-02-17 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| US20160367651A1 (en) | 2013-10-01 | 2016-12-22 | Mie University | T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation |
| WO2016015095A1 (en) | 2014-07-31 | 2016-02-04 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
| WO2016040900A1 (en) | 2014-09-14 | 2016-03-17 | Washington University | Personalized cancer vaccines and methods therefor |
| US10317402B2 (en) | 2014-12-03 | 2019-06-11 | Verik Bio, Inc. | Identification, selection and use of high curative potential T cell epitopes |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| BR112017022845A2 (pt) * | 2015-04-23 | 2018-07-17 | Nantomics, Llc | neoepítopos de câncer |
| EA201792501A1 (ru) * | 2015-05-13 | 2018-10-31 | Эйдженус Инк. | Вакцины для лечения и профилактики рака |
| EP3323070B1 (en) * | 2015-07-14 | 2024-05-08 | Personal Genome Diagnostics Inc. | Neoantigen analysis |
| ES2970865T3 (es) | 2015-12-16 | 2024-05-31 | Gritstone Bio Inc | Identificación, fabricación y uso de neoantígenos |
| WO2018136664A1 (en) | 2017-01-18 | 2018-07-26 | Ichan School Of Medicine At Mount Sinai | Neoantigens and uses thereof for treating cancer |
| EP3678699A1 (en) | 2017-09-07 | 2020-07-15 | University Of Oslo | Vaccine molecules |
-
2019
- 2019-09-27 MX MX2021003654A patent/MX2021003654A/es unknown
- 2019-09-27 SG SG11202101965QA patent/SG11202101965QA/en unknown
- 2019-09-27 IL IL281771A patent/IL281771B2/en unknown
- 2019-09-27 US US17/279,946 patent/US12462898B2/en active Active
- 2019-09-27 EP EP19773458.5A patent/EP3856957A1/en active Pending
- 2019-09-27 JP JP2021517009A patent/JP7585195B2/ja active Active
- 2019-09-27 KR KR1020217012734A patent/KR102902460B1/ko active Active
- 2019-09-27 BR BR112021005702A patent/BR112021005702A8/pt unknown
- 2019-09-27 CA CA3111903A patent/CA3111903A1/en active Pending
- 2019-09-27 WO PCT/EP2019/076210 patent/WO2020065023A1/en not_active Ceased
- 2019-09-27 CN CN201980063254.9A patent/CN112771214B/zh active Active
- 2019-09-27 AU AU2019346023A patent/AU2019346023B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020065023A1 (en) | 2020-04-02 |
| JP7585195B2 (ja) | 2024-11-18 |
| CA3111903A1 (en) | 2020-04-02 |
| CN112771214A (zh) | 2021-05-07 |
| BR112021005702A8 (pt) | 2022-11-08 |
| SG11202101965QA (en) | 2021-04-29 |
| AU2019346023A1 (en) | 2021-03-25 |
| US20210388438A1 (en) | 2021-12-16 |
| IL281771B1 (en) | 2025-04-01 |
| KR20210065171A (ko) | 2021-06-03 |
| BR112021005702A2 (pt) | 2021-06-22 |
| IL281771A (en) | 2021-05-31 |
| KR102902460B1 (ko) | 2025-12-19 |
| AU2019346023B2 (en) | 2024-12-12 |
| EP3856957A1 (en) | 2021-08-04 |
| IL281771B2 (en) | 2025-08-01 |
| CN112771214B (zh) | 2025-06-13 |
| JP2022502416A (ja) | 2022-01-11 |
| US12462898B2 (en) | 2025-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003654A (es) | Metodo para seleccionar neoepitopes. | |
| ECSP20078226A (es) | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas | |
| SV2017005355A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
| MX391279B (es) | Anticuerpos biespecíficos contra cd3 y cd20. | |
| ECSP17045736A (es) | Composiciones y métodos para anticuerpos dirigidos a bmp6 | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| CO2018001485A2 (es) | Diacuerpos monovalentes biespecificos que son capaces de unirse a b7 - h3 y cd3 | |
| PY1800237A (es) | Aislados de bacillus y usos de los mismos | |
| UY37564A (es) | Aislados de lysinibacillus y usos de los mismos | |
| MX370018B (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| CO2017002719A2 (es) | Anticuerpos anti-glucagón | |
| PE20191812A1 (es) | Compuestos y metodos para la reduccion celular especifica de tumor | |
| CL2017002728A1 (es) | Método para el tratamiento de cáncer | |
| AR088171A1 (es) | Anticuerpos anti-erbb3 y usos de los mismos | |
| MX373280B (es) | Anticuerpos anti-egfrviii y usos de los mismos. | |
| AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| MX2016013239A (es) | Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19. | |
| PE20171135A1 (es) | Metodos para seleccionar una linea de celulas t y donador de la misma para terapia celular adoptiva | |
| MX391051B (es) | Anticuerpos anti-cd47 y usos de los mismos. | |
| MX2017006167A (es) | Compuestos que interactúan con glicanos y métodos de uso. | |
| AR103726A1 (es) | Cristales de anticuerpos monoclonales anti-pd-1 humanos | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| AR095348A1 (es) | Medios de cultivo celular y métodos de producción de anticuerpos | |
| MX378368B (es) | Receptores de antigeno y usos de los mismos. | |
| CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares |